TaprenepagAlternative Names: PF 4217329; PF-04217329; Taprenepag isopropyl
Latest Information Update: 12 Nov 2016
At a glance
- Originator Pfizer
- Class Antiglaucomas
- Mechanism of Action Prostaglandin E EP2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-II for Glaucoma in USA (Topical)
- 30 Aug 2010 Phase-II development is ongoing in USA
- 11 Mar 2008 Phase-II clinical trials in Glaucoma in USA (unspecified route)